



10/18  
T

PATENT  
Customer No. 22,852  
Attorney Docket No. 06478.1478

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
Bernhard NIESWANDT ) Group Art Unit: 1644  
Application No.: 10/051,168 ) Examiner: M. HADDAD  
Filed: January 22, 2002 )  
For: MEDICAMENT FOR THE )  
PROTECTION AGAINST )  
THROMBOTIC DISEASES )

Commissioner for Patents  
Washington, DC 20231

Sir:

AMENDMENT

In response to the Office Action mailed October 22, 2002, the shortened statutory period for a response having been extended to April 22, 2003, by the attached Petition for Extension of Time and fee, please amend this application as follows:

IN THE SPECIFICATION:

Please amend the Specification as follows:

Page 3, amend the paragraph bridging lines 13-22 as follows:

Based on these results, it has now been found that a medicament is effective against thrombotic diseases if it comprises an active principal that induces an irreversible inactivation or degradation of a collagen receptor on thrombocytes. This active principal may be a chemical compound or a monoclonal or polyclonal antibody.

RECEIVED  
APR 25 2003  
TECH CENTER 1600/2900

RECEIVED  
APR 24 2003  
GROUP 1700

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com